1-MNA

Interest in 1-MNA grew from Polish pharmacological work demonstrating that, contrary to its historical classification as an inactive metabolite, it triggers systemic release of prostacyclin, a vasodilating and anti-platelet prostanoid ^[4]. Subsequent studies characterised anti-inflammatory and anti-thrombotic actions and explored its role in endothelial function, lipid handling and the formation of lipid droplets ^[1].

In diabetic (db/db) mice, four weeks of 1-MNA administration improved endurance exercise capacity and reduced post-exercise leukocytosis without altering glycaemic markers, alongside a favourable shift in insulin sensitivity ^[2]. Cell-based work using atomic force microscopy showed that 1-MNA can reverse tumour necrosis factor alpha induced endothelial dysfunction, correlating with restored nitric oxide and prostacyclin secretion ^[3].

Because 1-MNA is a natural NNMT product, its blood and urine levels also serve as biomarkers; elevated concentrations have been reported in coronary artery disease, complicating the interpretation of whether higher 1-MNA is protective or a compensatory response ^[1]. Human supplement data remain limited relative to the extensive rodent and in vitro literature.

1-MNA is an endogenous metabolite normally present in blood and urine, and it has been well tolerated in rodent studies at pharmacological doses. Human safety data come mainly from its use as a dietary supplement and from its status as a natural nicotinamide metabolite; formal long-term clinical safety trials are limited. Because circulating 1-MNA is elevated in some cardiovascular conditions, individuals with existing heart or vascular disease should treat supplementation cautiously and consult a clinician. It should not be assumed to be equivalent to niacin or nicotinamide for treating deficiency.

1-MNA was for decades treated as an inert end-product of nicotinamide methylation and used chiefly as a urinary biomarker of niacin metabolism. Beginning in the mid-2000s, researchers at the Jagiellonian Centre for Experimental Therapeutics and collaborators in Poland reported that it actively releases prostacyclin and possesses anti-thrombotic and anti-inflammatory properties, prompting its development as a candidate agent and, later, its appearance in the supplement market.

1-MNA has a modest but genuine research base, with credible rodent and cell studies supporting anti-inflammatory and endothelial actions. Within the nootropic and longevity community it is discussed as a NAD-adjacent metabolite, though enthusiasm outpaces the sparse human evidence. Its dual identity as both a putative protective agent and a disease biomarker makes claims about optimal levels genuinely uncertain.